Johnson & Johnson has been told to pay $257.7 million by a jury in Louisiana for claiming that its antipsychotic Risperdal was superior to similar drugs and downplaying its link to diabetes.
J&J intends to appeal the decision. Spokesman Michael Heinley told Bloomberg that “we believe the jury was not appropriately instructed on applicable legal standards and that critical and highly relevant evidence was excluded".
